BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H. Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. Front Neurosci 2016;10:201. [PMID: 27303254 DOI: 10.3389/fnins.2016.00201] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Nguyen DT, Jiang J. G protein-coupled receptors in acquired epilepsy: Druggability and translatability. Prog Neurobiol 2019;183:101682. [PMID: 31454545 DOI: 10.1016/j.pneurobio.2019.101682] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
2 Alachkar A, Khan N, Łażewska D, Kieć-Kononowicz K, Sadek B. Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats. Neuropsychiatr Dis Treat 2019;15:531-42. [PMID: 30863075 DOI: 10.2147/NDT.S193125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Hagenow S, Affini A, Pioli EY, Hinz S, Zhao Y, Porras G, Namasivayam V, Müller CE, Lin JS, Bezard E, Stark H. Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson's Disease. J Med Chem 2021;64:8246-62. [PMID: 34107215 DOI: 10.1021/acs.jmedchem.0c00914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hellman LT, Akula S, Thorpe M, Fu Z. Tracing the Origins of IgE, Mast Cells, and Allergies by Studies of Wild Animals. Front Immunol 2017;8:1749. [PMID: 29312297 DOI: 10.3389/fimmu.2017.01749] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
5 Li Z, Xiao X, Xue Y, Zhou H, Huang C, Zhu M, Zhuang T, Chen Y, Huang L. Discovery of a novel class of benzoxazole derivatives as histamine H3 receptor ligands for the treatment of neuropathic pain. Bioorg Chem 2022;127:106039. [PMID: 35872397 DOI: 10.1016/j.bioorg.2022.106039] [Reference Citation Analysis]
6 Affini A, Hagenow S, Zivkovic A, Marco-Contelles J, Stark H. Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease. Eur J Med Chem 2018;148:487-97. [PMID: 29477889 DOI: 10.1016/j.ejmech.2018.02.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
7 Sandiego CM, Barret O, Lee H, Alagille D, Amenta A, Fowles K, Holden D, Seibyl JP, Tamagnan G. Imaging histamine H3 receptors with [18 F]FMH3: Test-retest and occupancy studies in the non-human primate. Synapse 2019;73:e22096. [PMID: 30835877 DOI: 10.1002/syn.22096] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Eissa N, Venkatachalam K, Jayaprakash P, Yuvaraju P, Falkenstein M, Stark H, Sadek B. Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism. Pharmaceuticals 2022;15:929. [DOI: 10.3390/ph15080929] [Reference Citation Analysis]
9 Kuder KJ, Łażewska D, Kaleta M, Latacz G, Kottke T, Olejarz A, Karcz T, Fruziński A, Szczepańska K, Karolak-Wojciechowska J, Stark H, Kieć-Kononowicz K. Synthesis and biological activity of novel tert-amylphenoxyalkyl (homo)piperidine derivatives as histamine H3R ligands. Bioorg Med Chem 2017;25:2701-12. [PMID: 28372935 DOI: 10.1016/j.bmc.2017.03.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bautista-Aguilera ÓM, Hagenow S, Palomino-Antolin A, Farré-Alins V, Ismaili L, Joffrin PL, Jimeno ML, Soukup O, Janočková J, Kalinowsky L, Proschak E, Iriepa I, Moraleda I, Schwed JS, Romero Martínez A, López-Muñoz F, Chioua M, Egea J, Ramsay RR, Marco-Contelles J, Stark H. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases. Angew Chem Int Ed Engl 2017;56:12765-9. [PMID: 28861918 DOI: 10.1002/anie.201706072] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
11 Schaller D, Hagenow S, Stark H, Wolber G. Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands. PLoS One 2019;14:e0218820. [PMID: 31237914 DOI: 10.1371/journal.pone.0218820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
12 Khanfar MA, Reiner D, Hagenow S, Stark H. Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands. Bioorg Med Chem 2018;26:4034-46. [PMID: 29960729 DOI: 10.1016/j.bmc.2018.06.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
13 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Aziz H, Mahmood A, Zaib S, Saeed A, El-seedi HR, Pelletier J, Sévigny J, Iqbal J. Synthesis, characterization, alkaline phosphatase inhibition assay and molecular modeling studies of 1-benzylidene-2-(4-tert- butylthiazol-2-yl) hydrazines. Journal of Biomolecular Structure and Dynamics 2021;39:6140-53. [DOI: 10.1080/07391102.2020.1802336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Łażewska D, Zaręba P, Godyń J, Doroz-Płonka A, Frank A, Reiner-Link D, Bajda M, Stary D, Mogilski S, Olejarz-Maciej A, Kaleta M, Stark H, Malawska B, Kieć-Kononowicz K. Biphenylalkoxyamine Derivatives-Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. Molecules 2021;26:3580. [PMID: 34208297 DOI: 10.3390/molecules26123580] [Reference Citation Analysis]
16 Malek R, Arribas RL, Palomino-antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-iriepa D, Godyń J, Panek D, Malawska B, Głuch-lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-contelles J, Kiec-kononowicz K, Egea J, de los Ríos C, Ismaili L. New Dual Small Molecules for Alzheimer’s Disease Therapy Combining Histamine H 3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition. J Med Chem 2019;62:11416-22. [DOI: 10.1021/acs.jmedchem.9b00937] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
17 Soliani A, Kubota SM, Corrêa MF, Cerutti SM, Fernandes JPS. Differential contribution of H3R antagonism by LINS01 compounds on memory, anxiety-like behaviour and spontaneous locomotor activity in healthy rats. Behavioural Brain Research 2020;377:112230. [DOI: 10.1016/j.bbr.2019.112230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther 2019;200:69-84. [PMID: 31028835 DOI: 10.1016/j.pharmthera.2019.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
19 Hauwert NJ, Mocking TAM, Da costa pereira D, Lion K, Huppelschoten Y, Vischer HF, De esch IJP, Wijtmans M, Leurs R. A Photoswitchable Agonist for the Histamine H 3 Receptor, a Prototypic Family A G‐Protein‐Coupled Receptor. Angew Chem 2019;131:4579-83. [DOI: 10.1002/ange.201813110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
20 Bajda M, Łażewska D, Godyń J, Zaręba P, Kuder K, Hagenow S, Łątka K, Stawarska E, Stark H, Kieć-Kononowicz K, Malawska B. Search for new multi-target compounds against Alzheimer's disease among histamine H3 receptor ligands. Eur J Med Chem 2020;185:111785. [PMID: 31669851 DOI: 10.1016/j.ejmech.2019.111785] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
21 Vanda D, Zajdel P, Soural M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. European Journal of Medicinal Chemistry 2019;181:111569. [DOI: 10.1016/j.ejmech.2019.111569] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
22 Falkenstein M, Reiner-Link D, Zivkovic A, Gering I, Willbold D, Stark H. Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation. Bioorg Med Chem 2021;50:116462. [PMID: 34695709 DOI: 10.1016/j.bmc.2021.116462] [Reference Citation Analysis]
23 Lutsenko K, Hagenow S, Affini A, Reiner D, Stark H. Rasagiline derivatives combined with histamine H3 receptor properties. Bioorganic & Medicinal Chemistry Letters 2019;29:126612. [DOI: 10.1016/j.bmcl.2019.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
24 Hauwert NJ, Mocking TAM, Da Costa Pereira D, Lion K, Huppelschoten Y, Vischer HF, De Esch IJP, Wijtmans M, Leurs R. A Photoswitchable Agonist for the Histamine H3 Receptor, a Prototypic Family A G-Protein-Coupled Receptor. Angew Chem Int Ed Engl 2019;58:4531-5. [PMID: 30735597 DOI: 10.1002/anie.201813110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
25 Schaller D, Hagenow S, Alpert G, Naß A, Schulz R, Bermudez M, Stark H, Wolber G. Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. ACS Med Chem Lett 2017;8:648-53. [PMID: 28626527 DOI: 10.1021/acsmedchemlett.7b00118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
26 Jankowska A, Wesołowska A, Pawłowski M, Chłoń-rzepa G. Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer’s Disease. CMC 2020;27:5351-73. [DOI: 10.2174/0929867326666190620095623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Albertini C, Salerno A, Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. Med Res Rev 2021;41:2606-33. [DOI: 10.1002/med.21699] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
28 Ghamari N, Dastmalchi S, Zarei O, Arias-Montaño JA, Reiner D, Ustun-Alkan F, Stark H, Hamzeh-Mivehroud M. In silico and in vitro studies of two non-imidazole multiple targeting agents at histamine H3 receptors and cholinesterase enzymes. Chem Biol Drug Des 2020;95:279-90. [PMID: 31661597 DOI: 10.1111/cbdd.13642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]